title: Accumulation of cholestatic lipoproteins in ANIT-treated human apolipoprotein A-I transgenic rats is diminished through dose-dependent apolipoprotein A-I activation of LCAT.
abstract: Administration of alpha-naphthylisothiocyanate (ANIT) to rats induces changes to plasma lipids consistent with cholestasis. We have previously shown (J. Lipid Res. 37 (1996) 1086) that animals treated with ANIT accumulate large amounts of free cholesterol (FC) and phospholipid (PL)-rich cholestatic lipoproteins in the LDL density range by 48 h. This lipid was cleared by 120 h through apparent movement into HDL with concomitant cholesteryl ester (CE) production. It was hypothesised that the clearance was mediated through the movement of the PL and FC into apolipoprotein A-I (apo A-I) containing lipoproteins followed by LCAT esterification to form CE. To test this hypothesis, rats overexpressing various amounts of human apo A-I (TgR[HuAI] rats) were treated with ANIT (100 mg/kg) and the effect of plasma apo A-I concentration on plasma lipids and lipoprotein distribution was examined. In untreated TgR[HuAI] rats, human apo A-I levels were strongly correlated to plasma PL (r(2)=0. 94), FC (r(2)=0.93) and CE (r(2)=0.90), whereas in ANIT-treated TgR[HuAI] rats, human apo A-I levels were most strongly correlated to CE levels (r(2)=0.80) and an increased CE/FC ratio (r(2)=0.62) and the movement of cholestatic lipid in the LDL to HDL. Since LCAT activity was not affected by ANIT treatment, these results demonstrate that the ability of LCAT to esterify the plasma FC present in cholestatic liver disease is limited by in vivo apo A-I activation of the cholestatic lipid and not by the catalytic capacity of LCAT.
authors.affiliation: Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Canada.
authors.forename: J W
authors.initials: JW
authors.lastname: Chisholm
authors.forename: J R
authors.initials: JR
authors.lastname: Paterniti
authors.forename: P J
authors.initials: PJ
authors.lastname: Dolphin
mesh_terms: D015058:1-Naphthylisothiocyanate / Q000494:pharmacology*; D000818:Animals; D030801:Animals, Genetically Modified; D016632:Apolipoprotein A-I / Q000172:deficiency* / Q000235:genetics / Q000494:pharmacology; D002779:Cholestasis / Q000097:blood / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D002788:Cholesterol Esters / Q000032:analysis; D015536:Down-Regulation; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation; D005227:Fatty Acids / Q000032:analysis; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry; D010743:Phospholipids / Q000097:blood* / Q000737:chemistry; D051381:Rats
chemical_list: D016632:Apolipoprotein A-I; D002788:Cholesterol Esters; D005227:Fatty Acids; D008077:Lipoproteins, LDL; D010743:Phospholipids; D015058:1-Naphthylisothiocyanate; D002784:Cholesterol